Nura Bio, a clinical-stage biopharmaceutical company, has successfully closed a Series A financing round, raising a total of over $140 million, including an additional $68 million recently. This funding will support the advancement of its lead drug candidate, NB-4746, a small molecule inhibitor targeting the SARM1 enzyme crucial for axon degeneration, which has completed Phase 1 studies in healthy volunteers. The company has appointed Dr. Shilpa Sambashivan as CEO, who has been instrumental in developing Nura Bio’s research pipeline. The Phase 1 trial demonstrated that NB-4746 was well-tolerated and effectively penetrated the brain, setting the stage for a Phase 1b/2 trial planned for 2025. Nura Bio's focus on preventing axon degeneration addresses a significant unmet need in treating various neurological disorders.